Inclusion Criteria:  Subjects who voluntarily participate in this clinical trial, are able to correctly understand and have signed the informed consent in writing; Male or female volunteer aged 18-55 years (inclusive); Body Mass Index (BMI) of 18-30 kg/m2 (inclusive); Subjects with chronic HBV infection, including immunotolerant subjects, treatment naïve subjects and treated subjects. Ability to cooperate with study staff and comply with the study requirements and follow the protocol-specified procedures.  Exclusion Criteria:  Subjects with liver diseases other than hepatitis B, including hepatitis C, hemochromatosis, primary sclerosing cholangitis; alcoholic, drug-related or autoimmune liver diseases; primary liver cancer and indeterminate nodules on liver imaging test; A history or manifestations of liver decompensation (e.g. Child-Pugh Class B or C, or ascites, gastrointestinal bleeding, hepatic encephalopathy or spontaneous bacterial peritonitis, etc.); Transient elastography at screening revealing FibroScan value ≥ 9 kPa or liver biopsy evidencing hepatic fibrosis within 24 months; The following laboratory findings: total serum bilirubin> 2×ULN; serum alpha-fetoprotein>50μg/L; serum albumin <3.5g/dL; international normalized ratio (INR)> 1.25; serum creatinine > 1.5×ULN; any laboratory outliers of clinical significance that in the investigator's opinion may interfere with the interpretation of efficacy or safety data; 12-lead ECG abnormalities with clinical significance; Pregnant or lactating women or women of child-bearing potential who are unwilling to take effective contraception throughout the course of the study (refer to Appendix 3 for details); Other factors that in the investigator's opinion would make it inappropriate for the subject to participate in the study.